Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal

Cell Metabolism

Volumn 20, Issue 2, 2014, Pages 280-294

  Sounni, Nor Eddine ^a   Cimino, Jonathan ^a   Blacher, Silvia ^a   Primac, Irina ^a   Truong, Alice ^a   Mazzucchelli, Gabriel ^a   Paye, Alexandra ^a   Calligaris, David ^a   Debois, Delphine ^a   De Tullio, Pascal ^a   Mari, Bernard ^b   De Pauw, Edwin ^a   Noel, Agnes ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBANILAMIDE DERIVATIVE; FATTY ACID SYNTHASE; HOMEODOMAIN PROTEIN; INDOLE DERIVATIVE; LIPID; NICOTINAMIDE; PYRROLE DERIVATIVE; RAG-1 PROTEIN; SORAFENIB; SUNITINIB;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; DISEASE COURSE; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; METABOLOMICS; METASTASIS; MOUSE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROTEOMICS; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; FATTY ACID SYNTHASES; HOMEODOMAIN PROTEINS; HUMANS; INDOLES; LIPIDS; METABOLOMICS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEOMICS; PYRROLES; RNA INTERFERENCE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84905731719     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2014.05.022     Document Type: Article

References (26)

1. V.R. Adams, and M. Leggas Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors Clin. Ther. 29 2007 1338 1353
2. J.Y. Bruce, J.M. Kolesar, H. Hammers, M.N. Stein, L. Carmichael, J. Eickhoff, S.A. Johnston, K.A. Binger, J.L. Heideman, and S.B. Perlman et al. A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies Cancer Chemother. Pharmacol. 73 2014 485 493
3. E.B. Butler, Y. Zhao, C. Muñoz-Pinedo, J. Lu, and M. Tan Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance Cancer Res. 73 2013 2709 2717
4. E. Currie, A. Schulze, R. Zechner, T.C. Walther, and R.V. Farese Jr. Cellular fatty acid metabolism and cancer Cell Metab. 18 2013 153 161
5. J.M. Ebos, and R.S. Kerbel Antiangiogenic therapy: impact on invasion, disease progression, and metastasis Nat Rev Clin Oncol 8 2011 210 221
6. J.M. Ebos, C.R. Lee, W. Cruz-Munoz, G.A. Bjarnason, J.G. Christensen, and R.S. Kerbel Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
7. J.M. Ebos, C.R. Lee, and R.S. Kerbel Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy Clin. Cancer Res. 15 2009 5020 5025
8. O. Feron Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells Radiother. Oncol. 92 2009 329 333
9. S. Giuliano, and G. Pagès Mechanisms of resistance to anti-angiogenesis therapies Biochimie 95 2013 1110 1119
10. A.W. Griffioen, L.A. Mans, A.M. de Graaf, P. Nowak-Sliwinska, C.L. de Hoog, T.A. de Jong, F.A. Vyth-Dreese, J.R. van Beijnum, A. Bex, and E. Jonasch Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients Clin. Cancer Res. 18 2012 3961 3971
11. R.K. Jain, D.G. Duda, J.W. Clark, and J.S. Loeffler Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nat. Clin. Pract. Oncol. 3 2006 24 40
12. J.W. Kim, I. Tchernyshyov, G.L. Semenza, and C.V. Dang HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia Cell Metab. 3 2006 177 185
13. I. Nakajima, S. Muroya, R. Tanabe, and K. Chikuni Extracellular matrix development during differentiation into adipocytes with a unique increase in type V and VI collagen Biol. Cell 94 2002 197 203
14. A. Noël, M.C. De Pauw-Gillet, G. Purnell, B. Nusgens, C.M. Lapiere, and J.M. Foidart Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts Br. J. Cancer 68 1993 909 915
15. M. Pàez-Ribes, E. Allen, J. Hudock, T. Takeda, H. Okuyama, F. Viñals, M. Inoue, G. Bergers, D. Hanahan, and O. Casanovas Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
16. S. Schoors, K. De Bock, A.R. Cantelmo, M. Georgiadou, B. Ghesquière, S. Cauwenberghs, A. Kuchnio, B.W. Wong, A. Quaegebeur, and J. Goveia et al. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis Cell Metab. 19 2014 37 48
17. B. Sennino, T. Ishiguro-Oonuma, Y. Wei, R.M. Naylor, C.W. Williamson, V. Bhagwandin, S.P. Tabruyn, W.K. You, H.A. Chapman, and J.G. Christensen et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors Cancer Discov 2 2012 270 287
18. M. Singh, S.S. Couto, W.F. Forrest, A. Lima, J.H. Cheng, R. Molina, J.E. Long, P. Hamilton, A. McNutt, and I. Kasman et al. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models J. Pathol. 227 2012 417 430
19. P. Sonveaux, F. Végran, T. Schroeder, M.C. Wergin, J. Verrax, Z.N. Rabbani, C.J. De Saedeleer, K.M. Kennedy, C. Diepart, and B.F. Jordan et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice J. Clin. Invest. 118 2008 3930 3942
20. N.E. Sounni, and A. Noel Targeting the tumor microenvironment for cancer therapy Clin. Chem. 59 2013 85 93
21. N.E. Sounni, L. Devy, A. Hajitou, F. Frankenne, C. Munaut, C. Gilles, C. Deroanne, E.W. Thompson, J.M. Foidart, and A. Noel MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression FASEB J. 16 2002 555 564
22. D. Strumberg Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment Drugs Today (Barc) 41 2005 773 784
23. A.A. van der Veldt, M.R. Meijerink, A.J. van den Eertwegh, A. Bex, G. de Gast, J.B. Haanen, and E. Boven Sunitinib for treatment of advanced renal cell cancer: primary tumor response Clin. Cancer Res. 14 2008 2431 2436
24. M.G. Vander Heiden Targeting cancer metabolism: a therapeutic window opens Nat. Rev. Drug Discov. 10 2011 671 684
25. J.C. Welti, T. Powles, S. Foo, M. Gourlaouen, N. Preece, J. Foster, S. Frentzas, D. Bird, K. Sharpe, and A. van Weverwijk et al. Contrasting effects of sunitinib within in vivo models of metastasis Angiogenesis 15 2012 623 641
26. S. Wu, J.J. Chen, A. Kudelka, J. Lu, and X. Zhu Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis Lancet Oncol. 9 2008 117 123